Drug vacheysindhi 👏👏👏

[All_is_well]

Hyderabad: Mumbai-based Glenmark Pharmaceuticals has launched antiviral drug Favipiravir (FabiFlu) for the treatment of mild to moderate COVID-19 patients. The company has received manufacturing and marketing approval from India’s drug regulator, under an accelerated approval process looking at the rarity of the situation and severity of the disease, making it the first oral Favipiravir-approved medication in India.

Sujesh Vasudevan, president, India Formulations, Middle East and Africa, Glenmark Pharmaceuticals, told Telangana Today, “We have already started manufacturing the drug for India. We definitely will look for opportunities in other markets. We will be looking to cater to Middle East nations as there is growing interest.”
“We chose to initiate work on Favipiravir, as it has proven in-vitro activity against SARS CoV2 virus, which is the virus responsible for COVID-19. And it has a wide therapeutic safety margin for COVID-19 at the dose that we administer,” he added.

Favipiravir has been approved in Japan since 2014 for the treatment of novel or re-emerging influenza virus infections. It is converted into an active phosphoribosylated form in cells and recognised as a substrate by viral RNA (ribonucleic acid) polymerase, thereby inhibiting RNA polymerase activity.

[BeautyQueen]

Edhi aina work avthundha 

[All_is_well]

Mana desi di anae sariki andhariki doubt 🤦..

inka China tho Emi fight cheysthamu..

[Assam_Bhayya]

Vaarni em gola chesthunnar ra babu India motham.

Dhenikante better tablets unnayi already India lo like Febrex plus (Chlorpheniramine Maleate + Paracetamol/Acetaminophen + Phenylephrine),  mild symptoms endhi severe nose block, fever, throat infection ku kuda baaga pani chesthadhi . 

[karthik25]

Approved drug kabatti s/e profile will be relatively good. 

Showing In-vitro activity is good. in-vivo models lo kuda chupiste we can bank on it. Insha Ganesha.. all goes well.

[Kool_SRG]

Glenmark Share next week bumper gain  ✌️

[sri_india]

103 rupees per tablet 

[Kalam_Youtheman]

2 hours ago, All_is_well said:

Hyderabad: Mumbai-based Glenmark Pharmaceuticals has launched antiviral drug Favipiravir (FabiFlu) for the treatment of mild to moderate COVID-19 patients. The company has received manufacturing and marketing approval from India’s drug regulator, under an accelerated approval process looking at the rarity of the situation and severity of the disease, making it the first oral Favipiravir-approved medication in India.

Sujesh Vasudevan, president, India Formulations, Middle East and Africa, Glenmark Pharmaceuticals, told Telangana Today, “We have already started manufacturing the drug for India. We definitely will look for opportunities in other markets. We will be looking to cater to Middle East nations as there is growing interest.”
“We chose to initiate work on Favipiravir, as it has proven in-vitro activity against SARS CoV2 virus, which is the virus responsible for COVID-19. And it has a wide therapeutic safety margin for COVID-19 at the dose that we administer,” he added.

Favipiravir has been approved in Japan since 2014 for the treatment of novel or re-emerging influenza virus infections. It is converted into an active phosphoribosylated form in cells and recognised as a substrate by viral RNA (ribonucleic acid) polymerase, thereby inhibiting RNA polymerase activity.

 

2 hours ago, All_is_well said:

Mana desi di anae sariki andhariki doubt 🤦..

inka China tho Emi fight cheysthamu..

 

2 hours ago, Assam_Bhayya said:

Vaarni em gola chesthunnar ra babu India motham.

Dhenikante better tablets unnayi already India lo like Febrex plus (Chlorpheniramine Maleate + Paracetamol/Acetaminophen + Phenylephrine),  mild symptoms endhi severe nose block, fever, throat infection ku kuda baaga pani chesthadhi . 

 

1 hour ago, karthik25 said:

Approved drug kabatti s/e profile will be relatively good. 

Showing In-vitro activity is good. in-vivo models lo kuda chupiste we can bank on it. Insha Ganesha.. all goes well.

 

1 hour ago, Kool_SRG said:

Glenmark Share next week bumper gain  ✌️

 

25 minutes ago, sri_india said:

103 rupees per tablet 

clinical trials raa royyyaaaa.....    hmmmm india lo clinical trials ante enti antaaaaru. entha chepppinaa waste a....

 

world lo mast drugs unnnayee same effect tho... but india approve chesindhii for glenmarkkk.... entha lancham theeskunnrooo india drug admins... I think asal aaaa deptrm undhaa mana india lo ani naaak doubt or over night a establish chesaaremo... inka mana royyyyas india lo thega jumping....  its a risk

[Catalpha]

In vitro lo test chesi animal studies or clinical trial lekunda drug manufacturing chestadanta howle gadu

[DummyVariable]

 

10 minutes ago, Catalpha said:

In vitro lo test chesi animal studies or clinical trial lekunda drug manufacturing chestadanta howle gadu

Being done in Japan and China 

[odhu_le_macha]

[Catalpha]

8 minutes ago, DummyVariable said:

 

Being done in Japan and China 

China believable, Japan hard to believe

[DummyVariable]

10 minutes ago, Catalpha said:

China believable, Japan hard to believe

Actually approved in both countries for influenza

The ongoing COVID-19 pandemic crisis has been complicated and worsened by the lack of recognized and/or FDA-approved drug therapies for the novel coronavirus. Concerted efforts to evaluate existing antiviral therapies for COVID-19 patients are now underway. Two drugs currently of significant interest and under investigation are favipiravir (“FAVI”) and remdesivir. As noted in our March 27, 2020 APSF Newsletter post, we cannot comment on the overall appropriateness, advisability, and/or efficacy of any specific COVID-19 therapy. However, reviews of the currently available online information and peer-review literature indicate that these drugs may be relatively uninvolved in significant drug-drug interactions (DDIs), especially compared to other antivirals such as CQ/HCQ and lopinavir/ritonavir.

Favipiravir

(T705 or Avigan) does not hold approval in the US for any indication but is currently approved in Japan and China for the treatment of influenza and/or novel influenza. The primary package insert is in Japanese but English language drug information for FAVI is readily available online.^1,2,3 It has been approved for experimental use and/or is in clinical trials in the US, Italy, Japan, and China to treat patients with the novel coronavirus.

FAVI is a pro-drug. It requires in vivo conversion via human hypoxanthine guanine phosphoribosyltransferase (HGPRT) to an active metabolite in order to exert an antiviral effect. Because acyclovir is known to be an in vitro inhibitor of HGPRT, it is a theoretical concern that co-administration of these two drugs could impair the efficacy of FAVI. The problematic drug pair of FAVI and acyclovir is not at all unlikely, since latent viral herpetic reactivation can occur with other viral or bacterial concomitant infections in medically challenged and critically ill COVID-19 patients.^4,5. Thus, clinicians prescribing acyclovir for a patient already receiving FAVI must consider the possibility of decreased FAVI efficacy against the novel coronavirus due to decreased prodrug conversion.

Final metabolism of FAVI is not thought to be primarily mediated by microsomal enzymes (i.e., the cytochrome P450 system), but rather by aldehyde oxidase (AO) and xanthine oxidase in the hepatocyte cytosol.⁶ There are no direct reports of the effect of AO inhibition on FPV, however the literature contains at least one reported in vitro DDI between a different AO substrate-inhibitor pair, namely zaleplon (an oral sedative-hypnotic) and cimetidine, respectively.⁷ So, although the literature lacks any definitive reports directly involving FAVI, clinicians should note that co-administration of the drug with AO inhibitors such as cimetidine, tamoxifen, phenothiazines, verapamil, amlodipine, nifedipine, loratidine, cyclobenzaprine, ondansetron, ketoconazole, and could theoretically raise blood levels of active FAVI metabolites.

Clinicians should also be aware that FAVI is associated with alterations in acetaminophen metabolism, specifically inhibition of acetaminophen sulfate formation.⁸ In order to avoid accumulation of toxic acetaminophen metabolites (such as NAPQI) while taking FAVI, the maximum acetaminophen dosage should not exceed 3000 mg per day. 

Finally, per the drug sheets, please note that FAVI, although not a CYP450 substrate, is a possible CYP2C8 inhibitor. Therefore, co-administration with CYP2C8 substrates such as paclitaxel, repaglinide and rosiglitazone (oral hypoglycemics), torasemide (loop diuretic), and buprenorphine may pose a risk for increased drug effects of these co-administered drugs.

Remdesivir

Remdesivir is an investigational drug, now in clinical trials in the US. Because COVID -19 is a RNA virus and remdesivir resembles an RNA subunit, incorporation of this drug into the viral RNA halts replication.⁹ Because this is not an FDA-approved drug, fully-developed US package insert information is unfortunately not available. Therefore, a distinct lack of rigorously verified DDI information is available to clinicians.

Remdesivir is apparently an in vitro substrate of CYP2C8, 2D6, and 3A4. However, the most current understanding is that in vivo remdesivir metabolism is dominated by hydrolase activity, which would suggest that the range of possible DDIs with clinically relevant CYP2C8/2D6/3A4 inhibitors and inducers is unlikely to occur.¹⁰

As part of our online search for remdesivir DDIs, we reviewed a website entitled “Interactions with Experimental COVID-19 Therapies”, compiled by the Liverpool Drug Interaction Group. This compilation contains tables that detail potential DDIs for , (as well as FAVI and other possible COVID-19 antiviral therapies), with numerous other medications spanning a wide range of therapeutic classes. However, in our brief acquaintance with this website, we have so far found it to be quite sensitive but rather non-specific. This reflects the mechanism-driven nature of the tabular content, which has not necessarily been rigorously validated by a search for empirically-verified findings.

For example, the database indicates that the combination of remdesivir with carbamazepine would yield significantly decreased remdesivir levels, when this has never been empirically demonstrated, and the quite minor contribution of CYP3A4 to remdesivir metabolism renders this much less likely than it might theoretically seem at first glance.⁸ So, while we cannot conclude that the specified DDI information pertaining to remdesivir has been rigorously verified, it seems that the website might be useful as an adjunct to direct targeted inquiries into potential DDIs involving remdesivir (and other possible COVID-19 therapeutic agents) as well as a potential, although we believe over-inclusive, reference for the clinician prescribing anti-viral therapies for the novel coronavirus.

Clinical Context

Because FAVI and remdesivir are so new, not all possible DDIs will have been anticipated in pre-marketing studies. The fact that there are few, if any, substantiated reports of DDIs in the peer-reviewed literature at present should not lull prescribing physicians into a false sense of security. Notwithstanding the lack of pre-existing clinical confirmation, problems may arise when these drugs are combined with other agents in complex regimens and seemingly inexplicable reactions can occur. These deleterious events may be a result of unexpected and previously undescribed DDIs as well as idiosyncratic side-effects. Clinical vigilance is warranted at all times when administering FAVI and remdesivir.

[BeautyQueen]

58 minutes ago, DummyVariable said:

 

Being done in Japan and China 

 

49 minutes ago, Catalpha said:

China believable, Japan hard to believe

Cute couple 

[Srin]

Source link edina untey share cheyandi